

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Tree of Knowledge International Corp.** (the "Issuer").

Trading Symbol: **CSE: TOKI; OTCBB: TOKIF**

Number of Outstanding Listed Securities (October 31, 2020): **253,238,010 Common Shares**

Date: **November 4, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer has been pursuing its business plan in accordance with the COVID-19 requirements and continues to monitor the effects that COVID-19 may have on its operations. Also see Item 3 below.

Due to COVID-19, the auditor of the Issuer was delayed in completing its Interim Financial Statements, Management Discussion and Analysis and related CEO and CFO Certificates for the period ended March 31, 2020 ("Interim Filings"). The Issuer applied to its principal regulator and was granted a Management Cease Trade Order ("MCTO"). The MCTO expired on July 15, 2020 and the Issuer prior to this expiry date, applied for an extension to this MCTO, however the Ontario Securities Commission, denied such extension request.

On July 15, 2020, the Ontario Securities Commission converted the MCTO to a failure to file cease trade order (“FFCTO”). During the FFCTO any person or company must not trade in or purchase a security of the Issuer for so long as the FFCTO remains in effect.

The Issuer was able to file its Interim Filings on September 22, 2020 and the FFCTO revoked on September 23, 2020.

Following the revocation of the FFCTO, on October 2, 2020 the Issuer announced that its common shares would begin trading again on the Canadian Securities Exchange on October 5, 2020.

2. Provide a general overview and discussion of the activities of management.

Management has spent the month actively pursuing its business plan.

On October 2, 2020, the Issuer also provided a 2020-21 business update. The Company announced that following its recent annual meeting, and as disclosed in its press release dated August 13, 2020, the Issuer has made significant changes in the board of directors and internal governance policy implementations. This included the appointment of Mr. Ommid John Faghani as the new CEO of the Company. In addition, the Company would like to announce that Mr. Faghani has assumed the roles of Chairman and interim Chief Financial Officer. Mr. Faghani is the president of Newland Financial Inc., a private financial, investment and lending company with a long history of successful financial and educational management. In addition, the Issuer has implemented significant cost cutting strategies to move on from the challenges of the past and support the plan of action for the next 12 months.

The Issuer is expanding its core clinical services into virtual care, mental health and wellness within its clinics and embarking on virtual technology, innovation, and knowledge to empower and engage both patients and care providers to achieve comprehensive integrative medical care and wellness. The Company is negotiating to establish a network of 12 clinics with over 200,000 patients and embarking on technology, innovation, and knowledge to empower and involve both patients and care providers to achieve comprehensive integrative medical care and wellness.

In addition, the Issuer’s multi-disciplinary clinics, along with Dr. Andrew Weil’s Centre of Integrative Medicine at the University of Arizona, are planning to start Post COVID-19 and Integrative Chronic Pain program collaborations. The need for comprehensive integrative care is felt in many areas of medicine, especially in Post COVID-19 recovered patients who are left with multiple organ chronic conditions as well as in chronic pain patients. The Andrew Weil Center for Integrative Medicine at the University of Arizona is internationally recognized for its innovative educational programs, evidence-based clinical practice, and research in the field of integrative medicine. Graduates of this program, including one of TOKI’s physician members, are now guiding more than 8 million patients to take a greater role in their health and healing.

The Issuer is focusing on using technology for lifting barriers to care that would combine advanced virtual patient education platforms with virtual and in-person clinical programs to enhance treatment outcomes for this pandemic era and the following recovery period. All of the Company’s clinics are strictly following health protocols to ensure the safety of our patients as well as our frontline medical staff.

The Company's strategy is focused on the overall wellness of patients that includes mental as well as physical health. Using My Wellness Coach App, Mypain.ca and ZENDOSE virtual educational and care platforms along with structured clinical programs, the Issuer intends to focus and become a leader in integrative medical care. The mypain.ca website will be the core of the Company's education and wellness programs. The Company is investing in developing this site to educate and guide patients with their treatment options and strategies.

COVID-19 has introduced a new chapter in telemedicine and telehealth. The Issuer is taking this opportunity to offer many products and services online. These include medical consultation as well as educational programs that include health education. The Company is working in conjunction with the Zendose application as the primary platform we are planning to use for providing services for mental wellness, depression, and anxiety. This platform provides online mental health assessments and, education and treatment according to patient needs. During the COVID-19 crisis, mental health and wellness have become more than ever a major health priority.

Ryerson University's Faculty of Science and the Company are continuing their research project to develop a new nanotechnology-enhanced delivery method for cannabinoids and other therapeutic molecules. Added to the initial goal of creating targeted treatments for pain conditions is a pioneering application to combat cancerous tumors. The Issuer is also continuing the human clinical trials for a proprietary therapeutic hand held ultrasound device.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was

determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Tree of Kindness, Inc., one of the Issuer's U.S. subsidiaries, is currently involved in a legal proceeding as a defendant. The Issuer is not liable to pay for the debts of Tree of Kindness, Inc. The plaintiff in this aforementioned legal proceeding is Brian Main and this matter relates to repayments under the loan described in Section 15. Please see Item 15 below for further details.

Tree of Knowledge (a subsidiary), the Issuer, and others, have been made aware of a Statement of Claim filed in the Ontario Superior Court of Justice on August 6, 2020. The claim alleges breach of contract, and other things, all related to a contract agreed to by Tree of Knowledge, Inc. Based on the information received to date, Management believes that Issuer has been misnamed by the Plaintiff such that there is no merit to the claims made against it. The claim seeks damages in the amount of \$11,200,000 as well as punitive damages of CAD\$500,000 and other relief including an order appointing a receiver/manager over all the assets, undertaking and property of TOKI. The Company is vigorously pursuing its defences.

On June 5, 2020, a lawsuit was filed against Tree of Kindness, Inc. and Tree of Knowledge, Inc. in respect of their premises. The companies were evicted from the premises, no longer have access to the property and equipment and effectively ceased operations there.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance
Common Shares	2,000,000	Pursuant to a Prior Contractual Commitment for M&A Services

15. Provide details of any loans to or by Related Persons.

One of the Issuer's subsidiaries owes one of its former principals – Brian Main an aggregate sum of US\$197,726.50. The subsidiary entered into a promissory note with Mr. Main dated effective September 1, 2018, to evidence this historical debt that existed prior to the reverse take-over of the Issuer in July 2018. The amount was due December 31, 2019 and bears no interest. This repayment was not made. In addition, the Issuer subsidiary entered into a grid promissory note dated effective October 1, 2018, with each of the current and former principals as to US\$145,839.60 for Brian Main and US\$285,305.52 for Michael Caridi. The amounts are due December 31, 2020, and bear no interest. The notes were repayable as to \$20,000 per month per note starting January 1, 2019. The repayments have not yet commenced. Brian Main has sued the subsidiary for repayment, see Item 12.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The use of cannabis and its general acceptance, particularly for medical uses, continues to grow in the United States, Canada and internationally, as evidenced by the increasing number of jurisdictions adopting regulations to govern its use. However, it is not legal at the federal level in the United States and Canada has yet to implement its legalization process. CBD, in particular has garnered recent attention for efficacy in a variety of products, most notably, for the treatment of rare epileptic related disorders in children, however, until recently the legal status of CBD in the United States at a federal level was also tied to cannabis generally.

On December 20, 2018, the Agriculture Improvement Act of 2018 (the "2018 Farm Bill") was passed into law. Marked as genuinely historic for the cannabis industry, the passing of the 2018 Farm Bill has removed all confusion associated with "industrial hemp". While the Issuer has always utilized organically sourced US Dept. of Agriculture approved industrial hemp in its products, "hemp", defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis," has now been officially removed from the Controlled Substances Act in the United States. While the Issuer is still assessing the various implications of the new law, the development is extremely positive for the Issuer and its future development plans in the U.S. and elsewhere. See "Narrative Description of the Business – Regulatory Considerations" in the Listing Statement.

CBD has also been cited for benefits in the treatment of schizophrenia, some forms of cancer, type 1 diabetes, Alzheimer's, post-traumatic stress disorder, pain and inflammation, anxiety, addictions, mood symptoms, insomnia and acne. See

“Narrative Description of the Business – Principal Products or Services” in the Listing Statement. A recent trend includes use of CBD in the beauty products industry. Evidence of the benefits appears to be primarily anecdotal, however, an increasing number of studies and trials are being conducted to test the efficacy of CBD, particularly internationally. There are also an increasing number of delivery methods including vaporizers, oils, sprays, creams, capsules and microencapsulation (a process for putting CBD into tiny capsules to make it more readily absorbed by the body). As demand increases we can expect to see a number of technological advances.

The safety of CBD and cannabis related products will remain of paramount importance for the Issuer and will continue to be a focus for consumers and regulators alike. Regulation of the industry is expected to increase, including new regulations anticipated from the US Food and Drug Administration (FDA). Despite these challenges and a general lack of access to banking, the cannabis industry has so far enjoyed access to capital markets. The situation is constantly evolving and there is a great degree of uncertainty over how matters will be settled, however, it is likely that these US states that have legalized cannabis will fight any prohibition on its use as they are receiving significant amounts of tax revenue from the sale of cannabis. See “Narrative Description of the Business – Regulatory Considerations” and “Risk Factors” in the Listing Statement.


Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1) except in respect of filing certain Monthly Progress Reports and an updated Annual Listing Statement.
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: November 4, 2020.

Ommid Faghani
Name of Director or Senior Officer


Signature

Director
Official Capacity

Issuer Details Name of Issuer TREE OF KNOWLEDGE INTERNATIONAL CORP.	For Month End October	Date of Report YY/MM/D 20/11/04
Issuer Address c/o Toronto Poly Clinic Unit 209, 5460 Yonge Street		
City/Province/Postal Code Toronto, Ontario M2N 6K7	Issuer Fax No. ()	Issuer Telephone No. 1-877-283-1569
Contact Name Ommid John Faghani	Contact Position Chairman	Contact Telephone No. (647) 607-9044
Contact Email Address oj@tokicorp.com	Web Site Address www.tokicorp.ca	